Perspective Therapeutics, Inc.

Listed Company

CATXCIK 0000728387NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-103.12M

Total Assets

$266.97M

Equity

$207.03M

Shares Out

113.93M

Op. Cash Flow

$-82.48M

Business

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering targeted alpha therapies that use lead-212 (212Pb) to deliver potent, tumor-focused radiation. It develops theranostic paired products—212Pb-based therapeutics and 203Pb imaging diagnostics—built around proprietary targeting peptides (e.g., VMT01, VMT-α-NET, PSV359) and a lead-specific chelator. The company operates a single operating segment focused on clinical development, manufacturing and supply of targeted alpha therapies, leveraging an in-house 212Pb generator and CMO partnerships. Its programs are distributed via clinical trial networks and regional manufacturing sites primarily across the United States with global collaborator engagements.

Summary from filing dated 2025-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2022 2022-12-31
Grant revenue	884,000	1	1	—	—
Research and development	84	42	21	—	881,000
General and administrative	30	27	21	—	7
Goodwill impairment	0	24	0	—	—
Loss on disposal of property and equipment	0	27,000	0	—	305,000
Total operating expenses	114	92	42	—	9
Operating loss	−114	−91	−41	—	−9
Interest income	8	11	934,000	—	618,000
Interest and other expense	−376,000	−48,000	—	—	—
Other income from a related party (Note 3)	1	0	2,000	—	0
Equity in loss of affiliate	−2,000	−8,000	−17,000	17,000	0
Total non-operating income, net	9	10	835,000	—	618,000
Net loss from continuing operations	−104	−80	−40	—	−8
Net gain (loss) from discontinued operations	514,000	−949,000	−9	—	−3
Net loss before deferred income tax benefit	−104	−81	−49	—	−11
Deferred income tax benefit	793,000	2	3	—	—
Net loss	−103	−79	−47	—	−11
Loss from continuing operations, Basic	−1.41	−1.22	−1.4	—	−0.06
Loss from continuing operations, Diluted	−1.41	−1.22	−1.4	—	—
Gain (loss) from discontinued operations, Basic	0.01	−0.01	−0.34	—	−0.02
Gain (loss) from discontinued operations, Diluted	0.01	−0.01	−0.34	—	—
Basic loss per share	−1.4	−1.23	−1.74	—	−0.08
Diluted loss per share	−1.4	−1.23	−1.74	—	—
Basic	74	64	27	—	142
Diluted	74	64	27	—	—
Unrealized gain (loss) on available-for-sale securities	161,000	−51,000	0	—	—
Comprehensive loss	−103	−79	−47	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-06-30
Cash and cash equivalents	31	62	9	21	56
Short-term investments	114	165	0	23	—
Accounts receivable, net of allowance for doubtful accounts: $375 and $543	6,000	116,000	1	1	—
Prepaid expenses and other current assets	4	4	1	443,000	435,000
Total current assets	148	231	17	53	59
Property and equipment, net	77	57	6	371,000	2
Right-of-use asset, net	2	2	747,000	0	512,000
Intangible assets, in-process research and development	40	50	50	0	—
Other assets, net	486,000	405,000	487,000	175,000	107,000
Total assets	267	341	98	58	64
Accounts payable and accrued expenses	21	10	7	2	966,000
Lease liability	623,000	957,000	46,000	0	268,000
Accrued personnel expenses	7	5	4	—	—
Note payable	56,000	52,000	49,000	—	—
Deferred Income (Note 3)	0	1	0	—	—
Total current liabilities	29	18	16	3	2
Lease liability, net of current portion	1	1	780,000	0	256,000
Note payable, net of current portion	2	2	2	0	—
Deferred Income, net of current portion (Note 3)	27	27	0	—	—
Deferred tax liability	2	2	5	0	—
Other noncurrent liabilities	386,000	55,000	0	—	—
Total liabilities	60	50	23	3	3
Commitments and contingencies (Note 16)	—	—	—	—	—
Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued	0	0	0	0	0
Common stock: $0.001 par value; authorized 750,000,000 shares; issued 74,337,990 and 70,671,464 shares	74,000	70,000	28,000	142,000	142,000
Additional paid-in capital	542	522	228	160	160
Accumulated other comprehensive income (loss)	110,000	−51,000	—	—	—
Accumulated deficit	−335	−232	−152	−106	−99
Total stockholders' equity	207	291	75	55	61
Total liabilities and stockholders' equity	267	341	98	58	64

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-06-30
Foreign currency adjustments	250,000	−65,000	—	—	—
Depreciation expense and amortization	3	2	986,000	—	—
Loss on disposal of property and equipment	0	27,000	22,000	305,000	0
Net accretion of discounts on available-for-sale securities	−3	−607,000	0	—	—
Loss on divestiture	0	59,000	4	0	0
In-process research and development impairment	10	0	—	—	—
Share-based compensation	9	5	4	983,000	1
Other, net	5,000	99,000	410,000	—	—
Accounts receivable	110,000	1	198,000	284,000	405,000
Inventory related to discontinued operations (Note 4)	0	11,000	359,000	—	—
Interest receivable	−142,000	−880,000	0	—	—
Prepaid expenses and other current assets	624,000	−2	−325,000	−151,000	46,000
Accounts payable and accrued expenses	147,000	2	2	692,000	236,000
Deferred Income	−1	28	0	—	—
Accrued personnel expenses	2	4	1	—	—
Other noncurrent liabilities	331,000	55,000	0	—	—
Net cash used in operating activities	−82	−18	−37	−10	−8
Additions to property and equipment	−13	−54	−1	−282,000	−266,000
Proceeds from the sale of property and equipment	0	335,000	0	—	0
Additions to other assets	−135,000	−72,000	−18,000	—	—
Maturities of available-for-sale securities	174	0	—	—	—
Purchases of available-for-sale securities	−120	−165	0	—	—
Proceeds from maturity of held-to-maturity investments	0	79	23	—	—
Purchases of held-to-maturity investments	0	−79	0	−35	0
Net cash provided by (used in) investing activities	41	−219	24	−29	−284,000
Repayment of notes payable	−52,000	−48,000	−68,000	0	0
Proceeds from sales of common stock, pursuant to exercise of warrants, net	0	125,000	0	—	0
Proceeds from sales of common stock, pursuant to exercise of options	371,000	1	554,000	28,000	60,000
Proceeds from the sales of common stock and Pre-funded Warrants, net	0	288	—	—	—
Proceeds from the issuance of common stock pursuant to the ATM, net	10	0	—	—	—
Net cash provided by financing activities	10	289	785,000	28,000	56,000
Net (decrease) increase in cash and cash equivalents	−31	52	−12	−39	−8
Property and equipment in accounts payable and accrued expenses	10	0	—	—	—
Recognition of operating lease liability and right-of-use asset	205,000	2	811,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro